Clinical trials: Gastric Diseases
Colorectal Cancer (CRC), Gastric Cancer (GC)
A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
The goal of this single-arm, open-label, prospective clinical trial is to evaluate the safety, feasibility, and preliminary antitumor activity of intratumoral oncolytic virus (H101, recombinant human type 5 adenovirus) combined…
- Conditions
- Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07850882
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jie Yuan，MD
Gastric Outlet Obstruction
EUS-guided Versus Laparoscopic Gastrojejunostomy for Malignant Gastric Outlet Obstruction
Gastric outlet obstruction (GOO) is a common complication of various types of malignancy arising from the pancreas, bile ducts, retroperitoneum and distal stomach.
- Trial name
- EATING (NCT05605327)
- Testing
- EUS-guided gastroenterostomy, Laparoscopic gastroenterostomy
- Volunteers
- 120 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Obesity, Weight Control
European Study to Evaluate Preliminary Safety and Efficacy of Multiple Obalon Gastric Balloons for 12 Weeks as an Aid for Weight Loss
The objective of this study is to evaluate the initial safety and preliminary effectiveness of the Obalon intragastric balloon system in European subjects with a BMI in the range of 27 - 35 kg/m^2
- Trial name
- NCT01718886
- Testing
- Obalon Gastric Balloon
- Where
- 2 sites in Belgium, France
- Volunteers
- 17 people
- Sponsor
- Obalon Therapeutics, Inc.
Esophageal Cancer, Lung Cancer
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens.
- Conditions
- Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer
- Trial name
- NCT00291473
- Testing
- CHP-HER2, CHP-NY-ESO-1
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Obesity
Central Nervous Processing of Visual Food Stimuli in Severely Obese Subjects
Recent evidence has pointed to distinct alterations of brain functions in obese subjects some of which may even be causative for their obesity.
- Trial name
- NCT01493583
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- Cantonal Hospital of St. Gallen
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Advanced Gastric Cancer
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior…
- Trial name
- NCT00519324
- Testing
- Everolimus
- Where
- 8 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Urothelial Bladder Cancer, Gastric Adenocarcinoma
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles…
- Conditions
- Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer
- Trial name
- NIRADO (NCT04779151)
- Testing
- Dostarlimab, Niraparib
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer (Advanced Stage)
Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors
This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer…
- Trial name
- NCT07645742
- Testing
- Alternate-Day Fasting (ADF), Time-Restricted Eating (TRE)
- Volunteers
- 90 people
- Sponsor
- West Virginia University
Gastric Cancer, Esophageal Cancer
PAN-study: Pan-Cancer Early Detection Study (PAN)
The PAN-cancer Early Detection study or PAN-study is a prospective cross-sectional observational case-control study evaluating whether Breath Biopsy can differentiate between patients with and without different cancer types by…
- Conditions
- Gastric Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- NCT03756597
- Testing
- ReCIVA, CASPER
- Where
- United Kingdom
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Owlstone Ltd
Gastroparesis, Diabetes Mellitus
Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes
The purpose of this study is to evaluate the acute effects of sitagliptin on postprandial glycemia, incretin hormones and blood pressure, and the relationship to gastric emptying, after a mashed potato meal in patients with type…
- Trial name
- NCT02324010
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Royal Adelaide Hospital
Advanced Gastric Cancer
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor…
- Trial name
- NCT00565370
- Testing
- Capecitabine, Cisplatin, Sorafenib
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Early Gastric Cancer
A Clinical Trial to Evaluate the Sensitivity and Specificity of "WAYMED Endo" Compared to the Endoscopists in Classifying Early Gastric Cancer (EGC) Based on the Depth of Invasion in Endoscopic Images
The purpose of this clinical trial is to prove that the prediction capability of 'WAYMED endo' is superior to that of the endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images.
- Trial name
- NCT06317103
- Testing
- WADYMED endo, Control group (the endoscopists)
- Where
- South Korea
- Volunteers
- 653 people
- Sponsor
- WAYCEN Inc
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Gastro Esophageal Reflux
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
- Trial name
- NCT06025773
- Testing
- Lansoprazole 15 mg, Lansoprazole 15mg/Calcium carbonate 600mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Pain, Obesity
IV Lidocaine on Postoperative Pain and QOR on Morbid Obese Patients Undergoing Bypass Surgery
Can Intraoperative systemic lidocaine decrease postoperative opioid consumption and improve quality of recovery after laparoscopic gastric bypass surgery? The hypotheses:does the use of intraoperative systemic lidocaine decrease…
- Trial name
- NCT01180660
- Testing
- Lidocaine Infusion, Normal Saline
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Northwestern University
Stomach Neoplasms
Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer
Combination regimens of 3 active drugs have shown promising activity in treatment of metastatic gastric cancer. Docetaxel combined with cisplatin and 5-fluorouracil (FU) yielded superior overall survival and response rates when…
- Trial name
- NCT00511446
- Testing
- docetaxel, oxaliplatin, capecitabine
- Where
- 10 sites in Germany
- Volunteers
- 56 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Upper Endoscopy, GLP1-R-related Disease
Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists
The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.
- Trial name
- NCT07006142
- Testing
- Modified Fasting Guidelines
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Liver Cirrhosis and Hepatoma., Gastric Variceal Bleeding
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic treatment.
- Trial name
- GVO-nadolol (NCT00567216)
- Testing
- Nadolol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.